About Us
Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. Inositec was founded in December 2015 as a spin-off of ETH Zurich.
Inositune Platform
Our drug discovery platform is based on inositol hexaphosphate, (IP6). By selectively replacing phosphate groups on IP6, we are able to obtain molecules with more favorable drug-like properties…
Learn more >
Product Pipeline
By modifying the physico-chemical properties of IP6 through chemical modifications, Inositec is building a pipeline of novel drugs, initially targeting vascular and renal calcification disorders.
Learn more >
Partnering
Inositec has an extensive drug discovery platform based on analogs of inositol. Initially, Inositec will pursue development of its lead compounds through preclinical proof of concept before partnering certain drug candidate and discovery assets…
Learn more >